Release Date: August 31, 2017
Expiration Date: August 31, 2018
Media: Print with online posttest, evaluation, and request for credit
This activity is designed to inform physicians about the current and developing strategies in treating patients with acute myeloid leukemia (AML) with FLT3 mutations.
Instructions for Participation/How to Receive Credit:
This activity is directed towards medical oncologists, primary care physicians, nurses, and nurse practitioners who treat and/or manage patients with AML. Surgical oncologists, radiation oncologists, pathologists, internists, fellows, physician assistants, and other health care providers are also invited to participate.
After participating in this CME/CE activity, learners should be better prepared to:
- Describe the biologic function of FLT3, its mutational subtypes, and the rationale behind targeted inhibition in AML
- Explain the development history leading to the approval of targeted therapeutic inhibitors in FLT3-mutated AML
- Discuss emerging treatment options and ongoing trials of FLT3 inhibitors
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor and Chairman
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Amir T. Fathi, MD, MSc
Assistant Professor of Medicine
Harvard Medical School
Director, Leukemia Program
Massachusetts General Hospital
Disclosure: Consultant: Celgene, Seattle Genetics, MedImmune, Amgen, Agios.
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians’ Education Resource®, LLC (PER®), and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.
This activity is funded by PER®
Off-Label Disclosure and Disclaimer
This continuing medical and nursing education activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC.
Contact information for questions about the activity:
Physicians’ Education Resource®, LLC
2 Clarke Drive
Cranbury, NJ 08512
Phone: (888) 949-0045